Tempest Therapeutics News and Activities

View the org chart displaying its 7 main executives

Most searched biographies at Tempest Therapeutics

• Matt Angel, Chief Executive Officer
• John Yee, Director
• Drake Richey, Director

Popular executive movements at Tempest Therapeutics

• John Yee has joined the company as Director  (posted on June 5 2026).
• Drake Richey has joined the company as Director  (posted on June 5 2026).
• Mike Raab, Chairman of the Board, has left the company  (posted on May 25 2026).

Click here to view some more movements at Tempest Therapeutics

Create your alert
to follow the executive moves at Tempest Therapeutics.

Tempest Therapeutics has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Tempest Therapeutics

• Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
• Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference | Tempest Therapeutics
• Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma | Tempest Therapeutics
• Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update | Tempest Therapeutics
• Tempest Extends Limited Duration Stockholder Rights Plan | Tempest Therapeutics
• Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial | Tempest Therapeutics
• Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs | Tempest Therapeutics
• Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
• Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Tempest Therapeutics
• Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
• View more press releases Close

Social media about Tempest Therapeutics

• Tempest Therapeutics on Wikipedia, Google News & Yahoo Finance
• Tempest Therapeutics on LinkedIn, X (Twitter) & YouTube